Teva Takeda Yakuhin Ltd.

Plus, news about Cyclacel Pharmaceuticals, MediciNova and Revolution Medicines: Teva will divest its Japan business venture to private equity firm: The company said Friday that it agreed to transfer all shares of Teva Takeda and its subsidiary Teva Takeda Yakuhin — its businesses that sell generics in Japan — to JKI, a fund managed by J-Will Partners. According to Teva, the divestment will allow Teva to focus on its innovative medicines business in Japan. — Katherine Lewin Rome Therapeutics’ layoffs: The “dark genome” biotech is prioritizing its pipeline and letting go of 17 employees, according to CEO Rosana Kapeller’s LinkedIn post on Thursday. The company is now focused on autoimmune and neurodegenerative diseases. “As we advance both of these programs toward the clinic, we’ll be deprioritizing unrelated areas of dark genome research,” she wrote. — Kyle LaHucik Cyclacel announces plan for strategic alternatives: The company is reviewing options on an “expedited basis” in order to preserve cash, adding that the board also told management to reduce operating costs. Its stock $CYCC was down about 12% on Friday. — Katherine Lewin MediciNova to present interim analysis for ALS drug: MediciNova CMO Kazuko Matsuda said in a statement there’s a “a positive correlation between the 6-month and 12-month data” for ibudilast in a Phase 2/3 trial that enrolled patients with amyotrophic lateral sclerosis. The data are set to be presented this week at the International Symposium on ALS/MND in Canada, and full trial results are expected in 2026. — Katherine Lewin Revolution Medicines raised a total of $862.5 million in its public offering, far more than the $600 million it initially set out to bring in. — Jaimy Lee